Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Hyperuricemia Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Hyperuricemia Overview | 9 | 1 |
| Pipeline Products for Hyperuricemia Comparative Analysis | 10 | 1 |
| Hyperuricemia Therapeutics under Development by Companies | 11 | 1 |
| Hyperuricemia Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Hyperuricemia Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Hyperuricemia Products under Development by Companies | 16 | 1 |
| Hyperuricemia Products under Investigation by Universities/Institutes | 17 | 1 |
| Hyperuricemia Companies Involved in Therapeutics Development | 18 | 8 |
| Allena Pharmaceuticals, Inc. | 18 | 1 |
| AstraZeneca Plc | 19 | 1 |
| CymaBay Therapeutics, Inc. | 20 | 1 |
| Jiangsu Hengrui Medicine Co., Ltd. | 21 | 1 |
| Nippon Chemiphar Co., Ltd. | 22 | 1 |
| Nobelpharma Co., Ltd. | 23 | 1 |
| Polaris Pharmaceuticals, Inc. | 24 | 1 |
| Teijin Pharma Limited | 25 | 1 |
| Hyperuricemia Therapeutics Assessment | 26 | 10 |
| Assessment by Monotherapy Products | 26 | 1 |
| Assessment by Combination Products | 27 | 1 |
| Assessment by Target | 28 | 2 |
| Assessment by Mechanism of Action | 30 | 2 |
| Assessment by Route of Administration | 32 | 2 |
| Assessment by Molecule Type | 34 | 2 |
| Drug Profiles | 36 | 22 |
| (allopurinol + lesinurad) Drug Profile | 36 | 2 |
| ALLN-346 Drug Profile | 38 | 1 |
| arhalofenate Drug Profile | 39 | 4 |
| febuxostat Drug Profile | 43 | 2 |
| JPH-367 Drug Profile | 45 | 1 |
| NC-2500 Drug Profile | 46 | 1 |
| NC-2700 Drug Profile | 47 | 1 |
| pegadricase Drug Profile | 48 | 2 |
| Pyruvic acid Drug Profile | 50 | 1 |
| SHR-4640 Drug Profile | 51 | 1 |
| Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia Drug Profile | 52 | 1 |
| Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia Drug Profile | 53 | 1 |
| TMX-049 Drug Profile | 54 | 1 |
| verinurad Drug Profile | 55 | 2 |
| XEN-102 Drug Profile | 57 | 1 |
| Hyperuricemia Dormant Projects | 58 | 1 |
| Hyperuricemia Discontinued Products | 59 | 1 |
| Hyperuricemia Product Development Milestones | 60 | 10 |
| Featured News &Press Releases | 60 | 1 |
| Jun 15, 2016: Scottish Medicines Consortium Accepts Adenuric (Febuxostat) for the Prevention and Treatment of Hyperuricaemia and Predicts Savings for NHS Scotland | 60 | 1 |
| May 23, 2016: Teijin Pharma s Feburic (Febuxostat) Approved as Indication for Cancer Chemotherapy-Induced Hyperuricemia | 61 | 1 |
| Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11 | 61 | 1 |
| Jun 30, 2015: New Indication for Teijin Pharma s Febuxostat in Europe | 62 | 1 |
| Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat | 63 | 1 |
| Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric | 64 | 1 |
| Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat | 64 | 1 |
| Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat | 65 | 1 |
| Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea | 66 | 1 |
| May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan | 66 | 1 |
| Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-67 | 67 | 1 |
| Jan 21, 2011: Teijin Pharma Receives Approval Of TMX-67 For Treating Hyperuricemia In Japan | 67 | 1 |
| Oct 27, 2010: Teijin Pharma Launches TMX-67 In Canada | 68 | 1 |
| Mar 09, 2010: Menarini Launches ADENURIC (Febuxostat) In Europe | 68 | 1 |
| Mar 05, 2010: Launch by Menarini and Ipsen of Adenuric (febuxostat) in France for the treatment of chronic hyperuricemia in gout | 68 | 2 |
| Appendix | 70 | 2 |
| Methodology | 70 | 1 |
| Coverage | 70 | 1 |
| Secondary Research | 70 | 1 |
| Primary Research | 70 | 1 |
| Expert Panel Validation | 70 | 1 |
| Contact Us | 70 | 1 |
| Disclaimer | 71 | 1 |